Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that
affects patients' function, quality of life, and ability to tolerate treatment. In certain patients …

Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents. It
often affects compliance to anticancer therapies as it frequently causes schedule delays …

Oral and gastrointestinal mucositis caused by high-dose chemotherapy and/or radiation
continues to be an important clinical problem. Fortunately, there have been strategic …

Rapamycin (sirolimus) is a macrolide immunosuppressant that inhibits the mechanistic
target of rapamycin (mTOR) protein kinase and extends lifespan in model organisms …

Oral and gastrointestinal mucositis due to cancer therapies such as high-dose
chemotherapy and/or radiation continues to be an important clinical problem. Fortunately …

Inhibitors of mechanistic target of rapamycin (mTOR inhibitors) are used as antiproliferative
immunosuppressive drugs and have many clinical applications in various drug …

Background Considerable progress has been made in our understanding of the biological
basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of …

Mammalian target of rapamycin (mTOR) inhibitors are used as potent immunosuppressive
agents in solid-organ transplant recipients (everolimus and sirolimus) and as antineoplastic …

Oral mucositis induced by conventional cytotoxic cancer therapies is a common and
significant clinical problem in oncology. Mucositis symptoms, which include severe pain …

Background Stomatitis is a class effect associated with the inhibition of mTOR and is
associated with everolimus therapy for breast cancer. Topical steroids might reduce …